COVIRIX Medical has been appointed Australia and New Zealand agent by Metropolis Holdings (Hong Kong) Limited for distributing the Rapid Antigen Test and PCR test kits for DiaCarta Inc of the US (https://diacarta.com/). Metropolis is a global distributor of the DiaCarta test kits. DiaCarta COVID-19 tests rank top 3 among FDA SARS-CoV-2 Reference Panel Tests and are approved by US FDA for emergency use.

DiaCarta is a leading translational genomic and personalized diagnostics company based in Richmond, California, with business operations in China. DiaCarta provides highly sensitive and advanced technologies that will change the landscape of precision medicine and molecular diagnostics by impacting healthcare treatment plans and the well-being of individuals around the world.

The DiaCarta Covid test has the following features:

RAPID & PRAGMATIC

Less than 2 hours per run.

OPEN ARCHITECTURE

DiaCarta diagnostic solutions run on globally most commonly installed PCR detection systems, including Bio-Rad CXF 384, ABI 7500 Fast DX and ABI QuantStudio 5, increase availability at global scale.

DESIGNED FOR EFFICIENCY

High throughput (381 samples per run), low detection threshold (LoD 50 copies) and minimal sample (2 ul) input needed, ease for sample collection.

HIGH SENSITIVITY

LoD 50, detecting 50 copies of viral RNA/ml with 95% confidence, enables early virus detection and diagnosis.

SAMPLE TYPES

Supporting saliva, NP, OP and sputum.

SCALABLE GLOBAL MANUFACTURING BASE

20+ million test units weekly manufacturing capacity.

For further reference, please check here for the DiaCarta test kit information or contact COVIRIX Medical for further discussion. 

On DiaCarta Rapid Antigen Test: QuantiVirus™ SARS-CoV-2 Antigen Rapid Home Test | DiaCarta, Inc.

The QuantiVirus™ SARS-CoV-2 Antigen Rapid Home Test Kit is a lateral flow chromatographic immunoassay intended for the qualitative detection of the nucleocapsid protein antigen from SARS- CoV-2. This test is available for home use with self-collected (unobserved) anterior nasal swab specimens directly from individuals aged 14 years and older, or with adult-collected anterior nasal specimens directly from individuals aged 2 years or older, who are suspected of COVID-19 by their healthcare provider within the first 7 days of symptom onset, or without symptoms or other epidemiological reasons to suspect COVID-19 infection.